Julio C. C. Lorenzi

Rockefeller University — United States

Immunology and Microbiology · Life Sciences

41h-index12.5kcitations91works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(35), SARS-CoV-2 and COVID-19 Research(24), HIV/AIDS drug development and treatment(21), Monoclonal and Polyclonal Antibodies Research(15), COVID-19 Clinical Research Studies(13)

Publications91 total

A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
Science Advances·2022· 20 citedOpen Access
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
2022· 8 citedOpen Access
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
The Lancet Microbe·2022· 73 citedOpen Access
Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing
Proceedings of the National Academy of Sciences·2022· 83 citedOpen Access
Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing
2021· 7 citedOpen Access
mediações no desenvolvimento de um tratamento para a COVID-19: pescando actantes
Sociedade e Cultura·2021· 1 citedOpen Access
Publisher Correction: Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Nature·2021· 1 citedOpen Access
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Immunity·2021· 307 citedOpen Access
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques
PLoS Pathogens·2021· 22 citedOpen Access
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
Nature·2021· 237 citedOpen Access
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Nature·2021· 143 citedOpen Access
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
2021· 47 citedOpen Access
Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants
2021· 17 citedOpen Access
Evolution of antibody immunity to SARS-CoV-2
Nature·2021· 1.7k citedOpen Access
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
Science Translational Medicine·2021· 76 citedOpen Access
Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA
Journal of Virology·2020· 67 citedOpen Access
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates
Journal of Virology·2020· 28 citedOpen Access
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Science Translational Medicine·2020· 511 citedOpen Access
COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research
Current Opinion in HIV and AIDS·2020· 11 citedOpen Access
Evolution of Antibody Immunity to SARS-CoV-2
2020· 209 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Michel C. Nussenzweig(40), Marina Caskey(30), Frauke Muecksch(21), Théodora Hatziioannou(21), Paul D. Bieniasz(21), Thiago Y. Oliveira(18), Christian Gaebler(16), Anna Gazumyan(16), Davide F. Robbiani(15), Lilian Nogueira(15), Fabian Schmidt(15), Pamela J. Björkman(14), Katrina G. Millard(13), Melissa Cipolla(13), Zijun Wang(12), Pilar Mendoza(12), Yiska Weisblum(12), Michael S. Seaman(12), Yehuda Z. Cohen(12), Alice Cho(10)